Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

3,000

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 28, 2030

Conditions
Advanced Solid Tumors
Interventions
DRUG

Biologically-informed multi-agent system (Quasar) including targeted drugs Osimertinib, chemotherapy pemetrexed, immunotherapy pembrolizumab et al. approved by China CDE.

Quasar is a biologically-informed multi-agent system developed based on multi-omics and multi-modal data. By integrating multidimensional information such as patients' demographic, clinical, and omics data (including DNA genotyping, whole-exome sequencing, transcriptome sequencing, etc.), it prioritizes standard treatment plans and recommends the optimal personalized treatment plan. Including targeted drugs, chemotherapy, immunotherapy approved by China CDE.

Trial Locations (1)

Unknown

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Langfang Branch), Langfang

All Listed Sponsors
lead

NING LI

OTHER